Literature DB >> 12362934

International Conference on Harmonisation; guidance on E11 clinical investigation of medicinal products in the pediatric population; availability. Notice.

.   

Abstract

The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled "E11 Clinical Investigation of Medicinal Products in the Pediatric Population." The guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The guidance sets forth critical issues in pediatric drug development and approaches to the safe, efficient, and ethical study of medicinal products in the pediatric population. The guidance is intended to encourage and facilitate the timely development of pediatric medicinal products internationally.

Entities:  

Mesh:

Year:  2000        PMID: 12362934

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  28 in total

1.  Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.

Authors:  Ying Hong; Kenneth G Kowalski; Jenny Zhang; Li Zhu; Mariaarantxa Horga; Richard Bertz; Marc Pfister; Amit Roy
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  A guide to rational dosing of monoclonal antibodies.

Authors:  Shuang Bai; Karin Jorga; Yan Xin; Denise Jin; Yanan Zheng; Lisa A Damico-Beyer; Manish Gupta; Meina Tang; David E Allison; Dan Lu; Yi Zhang; Amita Joshi; Mark J Dresser
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

Review 3.  Study designs in paediatric pharmacoepidemiology.

Authors:  Katia Verhamme; Miriam Sturkenboom
Journal:  Eur J Clin Pharmacol       Date:  2010-11-25       Impact factor: 2.953

4.  Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.

Authors:  Margaux Boehler; Shirin Bruderer; Ivan Ulč; Jasper Dingemanse
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

5.  A randomized two-way crossover bioequivalence study in healthy adult volunteers of paediatric zidovudine/lamivudine/nevirapine fast-disintegrating fixed-dose combination tablet.

Authors:  Anjali Joshi; Daniel Gbadero; Fredrick Esseku; Olufikayo J Adesanya; Moji C Adeyeye
Journal:  J Pharm Pharmacol       Date:  2016-11-18       Impact factor: 3.765

Review 6.  Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.

Authors:  Lucas Moreno; Andrew D J Pearson; Xavier Paoletti; Irene Jimenez; Birgit Geoerger; Pamela R Kearns; C Michel Zwaan; Francois Doz; Andre Baruchel; Josef Vormoor; Michela Casanova; Stefan M Pfister; Bruce Morland; Gilles Vassal
Journal:  Nat Rev Clin Oncol       Date:  2017-05-16       Impact factor: 66.675

Review 7.  Clinical pharmacology considerations in biologics development.

Authors:  Liang Zhao; Tian-hua Ren; Diane D Wang
Journal:  Acta Pharmacol Sin       Date:  2012-09-24       Impact factor: 6.150

8.  Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018.

Authors:  Irin Tanaudommongkon; Shogo John Miyagi; Dionna J Green; Janelle M Burnham; John N van den Anker; Kyunghun Park; Johanna Wu; Susan K McCune; Lynne Yao; Gilbert J Burckart
Journal:  Clin Pharmacol Ther       Date:  2020-06-22       Impact factor: 6.875

9.  Effects of body size and gender on the population pharmacokinetics of artesunate and its active metabolite dihydroartemisinin in pediatric malaria patients.

Authors:  Carrie A Morris; Beesan Tan; Stephan Duparc; Isabelle Borghini-Fuhrer; Donald Jung; Chang-Sik Shin; Lawrence Fleckenstein
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

10.  Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.

Authors:  S Payen; R Serreau; A Munck; Y Aujard; Y Aigrain; F Bressolle; E Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.